Ovarian cancer
- PMID: 24767708
- DOI: 10.1016/S0140-6736(13)62146-7
Ovarian cancer
Abstract
Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery and platinum-based cytotoxic chemotherapy. Although this treatment can be curative for most patients with early stage disease, most women with advanced disease will develop many episodes of recurrent disease with progressively shorter disease-free intervals. These episodes culminate in chemoresistance and ultimately bowel obstruction, the most frequent cause of death. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Targeted treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential for improved survival. The efficacy of screening, designed to detect the disease at an earlier and curable stage remains unproven, with key results expected in 2015.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Comment in
-
The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.Hum Genomics. 2016 Dec 28;10(1):40. doi: 10.1186/s40246-016-0096-9. Hum Genomics. 2016. PMID: 28031051 Free PMC article.
Similar articles
-
Management and Treatment of Recurrent Epithelial Ovarian Cancer.Hematol Oncol Clin North Am. 2018 Dec;32(6):965-982. doi: 10.1016/j.hoc.2018.07.005. Hematol Oncol Clin North Am. 2018. PMID: 30390768 Review.
-
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21. N Engl J Med. 2018. PMID: 30345884 Clinical Trial.
-
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005. Oncotarget. 2017. PMID: 28454085 Free PMC article.
-
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.J Oncol Pharm Pract. 2017 Sep;23(6):454-469. doi: 10.1177/1078155216657165. Epub 2016 Jun 29. J Oncol Pharm Pract. 2017. PMID: 27357817 Review.
-
[Abnormalities of DNA repair and gynecological cancers].Bull Cancer. 2017 Nov;104(11):971-980. doi: 10.1016/j.bulcan.2017.09.007. Epub 2017 Oct 18. Bull Cancer. 2017. PMID: 29054544 Review. French.
Cited by
-
Ovarian cancer treatment: The end of empiricism?Cancer. 2015 Sep 15;121(18):3203-11. doi: 10.1002/cncr.29481. Epub 2015 Jun 10. Cancer. 2015. PMID: 26096019 Free PMC article. Review.
-
Landscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List.J Pers Med. 2022 Sep 14;12(9):1503. doi: 10.3390/jpm12091503. J Pers Med. 2022. PMID: 36143288 Free PMC article.
-
Integrated Analysis of Prognostic and Immune Associated Integrin Family in Ovarian Cancer.Front Genet. 2020 Jul 17;11:705. doi: 10.3389/fgene.2020.00705. eCollection 2020. Front Genet. 2020. PMID: 32765584 Free PMC article.
-
Ferroptosis: A New Promising Target for Ovarian Cancer Therapy.Int J Med Sci. 2022 Oct 17;19(13):1847-1855. doi: 10.7150/ijms.76480. eCollection 2022. Int J Med Sci. 2022. PMID: 36438923 Free PMC article. Review.
-
Improved Prediction of Ovarian Cancer Using Ensemble Classifier and Shaply Explainable AI.Cancers (Basel). 2023 Dec 11;15(24):5793. doi: 10.3390/cancers15245793. Cancers (Basel). 2023. PMID: 38136346 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
